Cybin Spearheads Psychedelic Research Advancements

Cybin (TSE:CYBN) has released an update.

Cybin Inc. announced that its Chief Medical Officer, Amir Inamdar, and Director of Clinical Development, Ellen James, will participate in key discussions and presentations at the upcoming Interdisciplinary Conference on Psychedelic Research in Amsterdam. They will address clinical trial design for psychedelic treatments, pathways to marketing authorization, and present research on a novel DMT-based therapy for Major Depressive Disorder. This involvement highlights Cybin’s advancing role in the development of psychedelic-based treatments and their potential in mental healthcare.

For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.